drugset / Trial / NCT05202145
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).
Timeline
- Start
- 2022-01-11
- Primary completion
- 2022-03-21
- Completion
- 2022-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | — | Oral |
| Subject | MMF | Unknown | — | Oral |
| Subject | Tacrolimus | Small molecule | — | Oral |
| Subject | Vemircopan | Small molecule | — | Oral |
Indications
No indication recorded.